This site is intended for healthcare professionals only
LoginRegister
Novartis Loses India Patent on Heart Failure Drug VymadaNovartis Loses India Patent on Heart Failure Drug Vymada
EMA Committee approves update to Novo Nordisk Rybelsus label to reflect cardiovascular benefitsEMA Committee approves update to Novo Nordisk Rybelsus label to reflect cardiovascular benefits
CDSCO Launches Separate Online Provision for Subsequent Importers of Medical Devices, IVDsCDSCO Launches Separate Online Provision for Subsequent Importers of Medical Devices, IVDs
Aurobindo Pharma arm CuraTeQ Biologics incorporates new wholly owned subsidiary in MaltaAurobindo Pharma arm incorporates new wholly owned subsidiary in Malaysia
Natco Pharma gets USFDA EIR for Kothur Pharma divisionNatco Pharma gets USFDA EIR for Kothur Pharma division
Zydus Wellness acquires UK based Comfort ClickRoche to acquire 89bio for up to USD 3.5 billion
Zydus Liesciences secures USFDA okay for Duchenne Muscular Dystrophy drugLupin bags USFDA approval for Multiple myeloma treatment
Biocon Opens First US Manufacturing Facility in New Jersey, Invests USD 30 Million in ExpansionBiocon Biologics wins USFDA nod for Bosaya and Aukelso, Denosumab Biosimilars
Ravenbhel Gets SEC Nod to Market Bilastine, Montelukast FDC, Phase IV Trial MandatedCocrystals of Approved APIs to Be Treated as New Drugs, Clarifies CDSCO
India ranks among top global contributors in adverse event reporting: DCGIIndia ranks among top global contributors in adverse event reporting: DCGI
Marketers Linked to Defaulting Pharma Units Under DCGI LensMarketers Linked to Defaulting Pharma Units Under DCGI Lens
Intas Pharma Told to Revise Phase I, III Pembrolizumab Trial ProtocolIntas Pharma Secures CDSCO Panel Approval for Post-Marketing Study of Tacrolimus Enema
X